Compounds > sotalol
Page last updated: 2024-08-16

sotalol and salmeterol xinafoate

sotalol has been researched along with salmeterol xinafoate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baker, JG1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Coleman, RA; Johnson, M; Nials, AT; Sumner, MJ1
Bergendal, A; Lindén, A; Löfdahl, CG; Skoogh, BE; Ullman, A1

Other Studies

5 other study(ies) available for sotalol and salmeterol xinafoate

ArticleYear
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    British journal of pharmacology, 2005, Volume: 144, Issue:3

    Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.
    British journal of pharmacology, 1993, Volume: 108, Issue:2

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Electric Stimulation; Guinea Pigs; In Vitro Techniques; Isoproterenol; Lung; Male; Muscle Relaxation; Muscle, Smooth; Perfusion; Radioligand Assay; Rats; Salmeterol Xinafoate; Sotalol; Time Factors

1993
Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.
    Thorax, 1993, Volume: 48, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Carbachol; Dose-Response Relationship, Drug; Ethanolamines; Female; Formoterol Fumarate; Guinea Pigs; Muscle Relaxation; Salmeterol Xinafoate; Sotalol; Trachea

1993